Press Releases

Filter per year
December 13, 2024
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
December 11, 2024
Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
December 9, 2024
Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
December 7, 2024
Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
December 6, 2024
Press Release: Availability of the profit and loss information of Sanofi excluding Opella
November 15, 2024
Communiqué de presse - Sanofi renforce la bioproduction d’anticorps en France avec un investissement de plus de 40 millions d’euros sur son site de Lyon Gerland
November 15, 2024
Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
November 14, 2024
Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
November 6, 2024
Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis
October 25, 2024
Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
October 24, 2024
Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
October 21, 2024
Press Release: Sanofi and CD&R partner to fuel Opella’s ambitions in consumer healthcare
October 17, 2024
Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines
October 11, 2024
Press Release: Sanofi in discussions to sell a controlling stake in Opella
October 9, 2024
Press Release: New Beyfortus data featured at IDWeek reinforce real-world effectiveness against RSV disease and hospitalization in infants
September 27, 2024
Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
September 27, 2024
Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD
September 26, 2024
Press Release: Availability of the Q3 2024 Aide mémoire
September 25, 2024
Media Update: EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases
September 20, 2024
Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

Press Statements